Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
14.69
-0.02 (-0.14%)
At close: May 02, 2025, 3:59 PM
14.50
-1.26%
After-hours: May 02, 2025, 04:05 PM EDT
Company Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Bicara Therapeutics Inc. Common Stock
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Rachel Salazar |
Contact Details
Address: 116 Huntington Avenue Boston, Massachusetts United States | |
| Website | https://www.bicara.com |
Stock Details
| Ticker Symbol | BCAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002023658 |
| CUSIP Number | 055477103 |
| ISIN Number | US0554771032 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Angela Windt | Vice President & Head of Regulatory Affairs |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs |
| Gary Bostanxhi M.B.A. | Vice President of Finance & Controller |
| Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance |
| Rachel Salazar | SVice President of R&D Strategy and Operations |
| Sathish Hasige Ph.D. | Senior Vice President and Head of Technical Operations & Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Mar 28, 2025 | S-8 | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 4 | Filing |
| Mar 03, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 13, 2025 | 8-K | Current Report |